Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Devon S Conway

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
Neurology|March 27, 2019
What is the impact of socioeconomic status on multiple sclerosis?Devon S Conway
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|March 26, 2024
Extended interval dosing of natalizumab: More evidence in supportKarlo Toljan, Devon S Conway
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|April 11, 2026
The wearing-off effect with natalizumab: Back to the drawing boardSaira Afzal, Devon S Conway
Nature Reviews. Neurology|December 7, 2010
Multiple sclerosis: Mechanisms of disability accumulation in multiple sclerosisDevon S Conway, Jeffrey A Cohen
Multiple Sclerosis Journal - Experimental, Translational and Clinical|June 14, 2017
A case of presumed herpes keratouveitis in a patient treated with fingolimodMalissa C Ayers, Devon S Conway
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 27, 2021
Comorbidities require special attention in minorities with multiple sclerosisDevon S Conway, Claudia H Marck
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 28, 2014
Natalizumab and fingolimod: insight into their relative efficacies in clinical practiceDevon S Conway, Jeffrey A Cohen
Neurologic Clinics|November 18, 2023
Health, Wellness, and the Effect of Comorbidities on the Multiple Sclerosis Disease Course: Tackling the ModifiableDevon S Conway, Amy B Sullivan, Mary Rensel
Multiple Sclerosis Journal - Experimental, Translational and Clinical|May 8, 2024
The patient-reported wearing-off phenomenon with monoclonal antibody treatments for multiple sclerosisLindsey M Marian, Kathleen A Harris, Devon S Conway
Neurological Research|July 7, 2017
Survey-based assessment of the relationship between cognitive impairment and mentally stimulating activity in multiple sclerosisBriana C Prager, Amy S Nowacki, Devon S Conway
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Neurology|March 27, 2019
What is the impact of socioeconomic status on multiple sclerosis?Devon S Conway
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|March 26, 2024
Extended interval dosing of natalizumab: More evidence in supportKarlo Toljan, Devon S Conway
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|April 11, 2026
The wearing-off effect with natalizumab: Back to the drawing boardSaira Afzal, Devon S Conway
Nature Reviews. Neurology|December 7, 2010
Multiple sclerosis: Mechanisms of disability accumulation in multiple sclerosisDevon S Conway, Jeffrey A Cohen
Multiple Sclerosis Journal - Experimental, Translational and Clinical|June 14, 2017
A case of presumed herpes keratouveitis in a patient treated with fingolimodMalissa C Ayers, Devon S Conway
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 27, 2021
Comorbidities require special attention in minorities with multiple sclerosisDevon S Conway, Claudia H Marck
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 28, 2014
Natalizumab and fingolimod: insight into their relative efficacies in clinical practiceDevon S Conway, Jeffrey A Cohen
Neurologic Clinics|November 18, 2023
Health, Wellness, and the Effect of Comorbidities on the Multiple Sclerosis Disease Course: Tackling the ModifiableDevon S Conway, Amy B Sullivan, Mary Rensel
Multiple Sclerosis Journal - Experimental, Translational and Clinical|May 8, 2024
The patient-reported wearing-off phenomenon with monoclonal antibody treatments for multiple sclerosisLindsey M Marian, Kathleen A Harris, Devon S Conway
Neurological Research|July 7, 2017
Survey-based assessment of the relationship between cognitive impairment and mentally stimulating activity in multiple sclerosisBriana C Prager, Amy S Nowacki, Devon S Conway
Pageof 6